GeoVax Labs (NASDAQ:GOVX) Announces Earnings Results

GeoVax Labs (NASDAQ:GOVX) posted its quarterly earnings results on Thursday. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.49, Zacks reports.

GeoVax Labs Price Performance

GOVX traded down $0.10 during midday trading on Thursday, reaching $1.27. The company’s stock had a trading volume of 351,985 shares, compared to its average volume of 628,015. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The stock’s 50-day moving average is $1.71 and its 200-day moving average is $2.17.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a report on Thursday, February 27th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, GeoVax Labs currently has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.